secwatch.observer — SEC 8-K summary
======================================

Issuer:     NexImmune, Inc. (—)
CIK:        0001538210
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001538210-22-000028
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NexImmune pivots to AIM INJ platform, cuts workforce 30%, pauses two cell therapy trials
--------------------------------------------------------------------------------

- Strategic shift: focus on AIM INJ 'off-the-shelf' platform; pause NEXI-001 AML and NEXI-003 HPV trials, seek external partners.
- Workforce reduction from 74 to ~50 employees; approx $0.7M severance costs expected in Q4 2022.
- Cash $45.9M as of Sep 30, 2022 (down from $53.1M June 30); cash runway extended to Q3 2023 via restructuring.
- Q3 2022 net loss $14.7M ($0.60 loss per share) vs $14.6M ($0.65) prior year; R&D $11.1M, G&A $3.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/nexi-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001538210-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer